What the FDA labels say about taking them together
Drospirenone/estradiol and voriconazole
Drospirenone/estradiol's FDA label of March 2, 2026 names voriconazole in its drug interactions section; the voriconazole labels PlainMeds reads (3) do not name drospirenone/estradiol. The drospirenone/estradiol label: “The clinical impact for a woman taking a DRSP-containing combination hormone and chronic use of a CYP3A4/5 inhibitor is unknown. Substances decreasing the exposure and possibly diminishing the efficacy of estrogens and …”
Check it at the source: the drospirenone/estradiol FDA label on DailyMed (effective March 2, 2026, Bayer HealthCare Pharmaceuticals Inc.); the voriconazole FDA label on DailyMed (effective February 26, 2026, Roerig).
What does the drospirenone/estradiol label say about voriconazole?
Drospirenone/estradiol label, drug interactions… bleeding profile. Substances increasing the exposure of estrogens and progestins (enzyme inhibitors) Concomitant administration of moderate or strong CYP3A4 inhibitors such as azole antifungals (for example, ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (for example, clarithromycin, erythromycin), diltiazem, and grapefruit juice did increase the plasma concentrations of the estrogen or the progestin or both [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ]. …
Drospirenone/estradiol label, warnings and precautionsStrong CYP3A4 inhibitors include azole antifungals (for example, ketoconazole, itraconazole, voriconazole), human immunodeficiency virus (HIV)/hepatitis C virus (HCV) protease inhibitors (for example, indinavir, boceprevir), and clarithromycin [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ].
Source: FDA drug label (Angeliq), Bayer HealthCare Pharmaceuticals Inc., effective March 2, 2026 (SPL set 761834c2-6b61-4583-84c2-f1ca4a97c4f2), via openFDA; the full label on DailyMed
What does the voriconazole label say about drospirenone/estradiol?
Voriconazole's label (effective February 26, 2026) and its 2 other brand-application labels do not name drospirenone/estradiol in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (VFEND), NDA021630 (Pf Prism Cv), as published by Roerig, effective February 26, 2026 (SPL set ce3ef5cf-3087-4d92-9d94-9eb8287228db), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Drospirenone/estradiol | Voriconazole | |
|---|---|---|
| Labeled for | Menopause symptoms | Fungal infections |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $6.37 per tablet 0.25 mg-0.5 mg tablet | $1.88 per tablet 200 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once